09/09/2026
Myopia management is about more than correcting blurry vision. It’s about managing myopia progression. 👓
Childhood myopia can progress as children grow, making early detection and appropriate management an important part of children’s eye care.
MiYOSMART iQ builds on HOYA’s proven D.I.M.S. Technology with its Triple Enhanced Design:
🎯 Activated
Defocus segments positioned closer to the geometrical centre of the lens.
⚡ Powerful
Higher myopic defocus power within the treatment zone.
↔️ Extended
A larger treatment zone designed to provide myopic defocus across a wider area.
In a 12-month randomised controlled trial involving children aged 4–12, 9 out of 10 children showed no clinically relevant myopia progression with MiYOSMART iQ.¹
MiYOSMART iQ represents the next evolution in myopia control lens technology, giving Eye Care Professionals another evidence-based option to support the management of childhood myopia.
Discover MiYOSMART iQ and learn more about the latest in myopia management | https://www.hoyavision.com/au/vision-products/myopia-management/miyosmart-iq/
Disclaimers:
*Outcomes for myopic children aged 4 to 12 years and may vary per age group and other parameters at the start of MiYOSMART iQ treatment.
Approval and availability of MiYOSMART and MiYOSMART iQ spectacle lenses for myopia control vary by country; they are not approved or available for sale in all countries, including the U.S.
Footnote:
Clinically relevant myopia progression is a change in cycloplegic spherical equivalent refraction of ≥-0.50D
References:
1. Tse D.Y., Hon Y., Chun R. K., Leung T. W., Leung D. K. Y., To C. H., Lam C SY. Myopia Control Efficacy of Defocus Incorporated Multiple Segments Spectacle lens with Triple Enhanced Design: 12-month randomized controlled trial. Abstract 2523, ARVO 2026 Annual Meeting, Denver, USA. https://lnkd.in/gGU2HkbM (accessed date 28.05.2026)
2. HOYA data on file. HOYA MiYOSMART iQ spectacle lens clinical outcomes. 04/2026.